EUVIMEDEUVIMED entdecken
Crossref

Preparing for next-generation PrEP: awareness and willingness to use long-acting injectable cabotegravir among men who have sex with men and trans women across Asia

Heather-Marie A Schmidt iD, Curtis Chan iD, Polin Ung, Tiara Nisa, Jason J Ong iD, Warittha Tieosapjaroen iD, Kimberly E Green iD, Nittaya Phanuphak iD, Michael M Cassell, Nicky Suwandi, Hua Boonyapisomparn, Midnight Poonkasetwattana und 2 weitere

Sexual Health · 2025

DOI: 10.1071/sh25065 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Sexual Health, 2025. Verfasst von Heather-Marie A Schmidt und 13 weiteren Autor:innen. Beteiligte Einrichtung: UNAIDS, Geneva, Switzerland. Hauptthemen laut MEDLINE: Pre-Exposure Prophylaxis, HIV Infections, Pyridones, Health Knowledge, Attitudes, Practice. Die Arbeit nennt 38 Literaturangaben. Gefördert von: World Health Organization.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Pre-exposure prophylaxis (PrEP) use could be accelerated by offering alternatives that overcome key barriers associated with oral PrEP. This study aimed to understand willingness and preferences for long-acting injectable cabotegravir (CAB-LA) among gay men and other men who have sex with men (MSM), and transgender women (TGW) in Asia.

Methods

An online cross-sectional survey was conducted from May to November 2022 among HIV-negative or unknown status MSM and TGW aged ≥18 years across 15 and 11 Asian countries/territories, respectively. Survey items included awareness and use of PrEP and CAB-LA, willingness to use current and emerging PrEP options, and attitudes towards CAB-LA. Descriptive statistics and logistic regression were used to analyse associations with willingness to use CAB-LA.

Results

Among 11,870 MSM and 980 TGW, 21.4% (n = 2448) and 32.5% (n = 295) were aware of CAB-LA, respectively, and 17.2% (n = 2036) and 16.8% (n = 165) were willing to use it. CAB-LA was the most preferred PrEP option for 3.6% (n = 400) of MSM and 6.5% (n = 61) of TGW. Awareness and willingness varied across countries/territories and populations. Key benefits of CAB-LA included HIV protection (57.8% MSM, 46.8% TGW), no need for daily pills (42.6% MSM, 31.1% TGW) and longer-term protection (38.0% MSM, 23.6% TGW). Main concerns included cost (39.6% MSM, 22.1% TGW), side-effects (37.5% MSM, 22.2% TGW), insufficient knowledge (33.3% MSM, 20.6% TGW) and pain (21.4% MSM, 24.9% TGW).

Conclusions

Successful introduction of CAB-LA, or other new long-acting injectable PrEP options, in Asia will require strategies to raise awareness and demand-generation that responds to the perceived benefits and concerns of communities.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pre-Exposure ProphylaxisHIV InfectionsPyridonesHealth Knowledge, Attitudes, PracticeTransgender PersonsHomosexuality, MalePatient Acceptance of Health CareSexual and Gender MinoritiesAnti-HIV AgentsHumansMaleAdultCross-Sectional StudiesFemaleAsiaYoung AdultMiddle AgedAdolescentSurveys and QuestionnairesDiketopiperazines

Stichwörter der Autor:innen

AsiaHIV preventionHIV/AIDSattitudesgay and bisexual menhealth knowledgelong-acting injectable cabotegravirpracticepre-exposure prophylaxistransgender women

Substanzen

cabotegravirPyridonesAnti-HIV AgentsDiketopiperazines

Autor:innen und Institutionen

  • UNAIDS, Geneva, Switzerland.
  • World Health Organization, Avenue Appia, Geneva 1211, Switzerland.
  • Kirby Institute, UNSW Sydney, Sydney, NSW, Australia. Email: cchan@kirby.unsw.edu.au; bbavinton@kirby.unsw.edu.au.
  • UNAIDS office for Cambodia, Lao PDR and Malaysia, Phnom Penh, Cambodia. Email: ungp@unaids.org.
  • WHO Western Pacific Regional Office, Manila, the Philippines. Email: nisat@who.int.
  • Melbourne Sexual Health Centre, Alfred Health, Melbourne, Vic, Australia. Email: Jong@mshc.org.au, wtieosapjaroen@mshc.org.au.

ORCID-Profile: Heather-Marie A Schmidt, Curtis Chan, Jason J Ong, Warittha Tieosapjaroen, Kimberly E Green, Nittaya Phanuphak, Lei Zhang, Benjamin R Bavinton

Förderung

  • World Health Organization

Zitieren

APA

Schmidt, H. A., Chan, C., Ung, P., Nisa, T., Ong, J. J., Tieosapjaroen, W., Green, K. E., Phanuphak, N., Cassell, M. M., Suwandi, N., Boonyapisomparn, H., Poonkasetwattana, M., Zhang, L., & Bavinton, B. R. (2025). Preparing for next-generation PrEP: awareness and willingness to use long-acting injectable cabotegravir among men who have sex with men and trans women across Asia. Sexual Health. https://doi.org/10.1071/sh25065

Vancouver

Schmidt HA, Chan C, Ung P, Nisa T, Ong JJ, Tieosapjaroen W, et al. Preparing for next-generation PrEP: awareness and willingness to use long-acting injectable cabotegravir among men who have sex with men and trans women across Asia. Sexual Health. 2025. doi:10.1071/sh25065

BibTeX
@article{Schmidt2025,
  author = {Schmidt, Heather-Marie A and Chan, Curtis and Ung, Polin and Nisa, Tiara and Ong, Jason J and Tieosapjaroen, Warittha and Green, Kimberly E and Phanuphak, Nittaya and Cassell, Michael M and Suwandi, Nicky and Boonyapisomparn, Hua and Poonkasetwattana, Midnight and Zhang, Lei and Bavinton, Benjamin R},
  title = {Preparing for next-generation PrEP: awareness and willingness to use long-acting injectable cabotegravir among men who have sex with men and trans women across Asia},
  journal = {Sexual Health},
  year = {2025},
  doi = {10.1071/sh25065}
}
Kostenlos starten →